Navigation Links
Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
Date:2/13/2008

Competitive Advantages in Efficacy Will Drive Prescription Rates, According

to a New Report from Decision Resources

WALTHAM, Mass., Feb. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, following its approval in early 2009, Centocor/Janssen-Cilag's ustekinumab will become the clinical gold standard for psoriasis by 2011. Ustekinumab will achieve gold standard status because of its competitive advantages in long-term efficacy over Centocor/Schering- Plough/Mitsubishi Tanabe's Remicade and due to its superior effect on plaque clearance when compared to Amgen/Wyeth/Takeda's Enbrel.

According to the new report entitled Psoriasis: Ustekinumab to Emerge as New Clinical Gold Standard by 2011, ustekinumab has competitive advantages in efficacy, the area of the highest importance to surveyed physicians, and a superior safety and delivery profile when compared to Remicade. Surveyed dermatologists report that a drug's effect on plaque clearance is the attribute that most influences their prescribing decisions in psoriasis and clinical data shows that ustekinumab has advantages over sales-leading Enbrel on this attribute.

"Clinical data and thought leader opinion indicate that ustekinumab and Abbott/Eisai's Humira outperform Enbrel on efficacy and delivery measures," said Irene Koulinska, analyst at Decision Resources. "But the major improvement in efficacy offered by ustekinumab will earn it future gold- standard status."

About the Report

Psoriasis: Ustekinumab to Emerge as New Clinical Gold Standard by 2011 is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial endpoints to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
2. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
3. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
4. Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
5. REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
6. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
7. Solazyme Selected for National Institute of Standards and Technology Award
8. MyClyns(TM), a New Standard of Personal Protection, is Announced at the EMS and Firehouse Central EXPO
9. CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public
10. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
11. Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):